Reneo Q2 net loss $19.5M; STRIDE topline results expected Q4 2023

OnKure Therapeutics, Inc.

2023-Q2 EPS reported -$1.25

Net loss $19.5M ($0.65/share) vs $12.3M ($0.50) in Q2 2022.
Cash and investments $142.7M as of June 30; raised $68.3M gross in May offering.
Topline data from pivotal mavodelpar STRIDE study in PMM due in Q4 2023.
Over 130 patients enrolled in STRIDE AHEAD OLE study; criteria expanded to nDNA defects.
R&D expenses $14.4M (up from $8.1M) driven by clinical and manufacturing costs for mavodelpar.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

OnKure Therapeutics, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $19.5 million, or $0.65 per share, EPS $0.65 per share.

Period: the second quarter ended June 30, 2023
Net income: net loss of $19.5 million, or $0.65 per share
EPS: $0.65 per share
Result: reported results

Exact text from the filing

On August 10, 2023, Reneo Pharmaceuticals, Inc. (the “Company”) issued a press release reporting the Company’s financial results for the second quarter ended June 30, 2023

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-041275

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.